ArticleJournal of translational medicine2023

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.

Pier Vitale Nuzzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.